top of page
Smartlens IOP monitoring

IT'S THE TIME
TO DO MORE
ABOUT
GLAUCOMA

Blindness due to Glaucoma

What is Glaucoma?

A group of chronic and progressive eye diseases that permanently damage the optic nerve

Elevated eye pressure is the primary and only modifiable risk factor for Glaucoma, the leading cause of irreversible blindness worldwide 

 




Vision loss over time due to Glaucoma
 
15-20 %

of all Glaucoma patients are at severe stage with
a high risk of permanent
blindness 
        Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al
48.8%

of all mild and moderate patients are worsening
every 12  months
        Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al
38.1%

of all Glaucoma patients
permanently lose their vision
despite being treated
Why do people (still) go blind from glaucoma?, Susanne et al                                                                                   

 Glaucoma is not well controlled for the majority of patients 

How is Glaucoma treated?

With prescription eye drops and surgical interventions that can temporarily lower eye pressure.
For every 1 mmHg reduction in eye pressure, the risk of optic nerve damage decreases by 11%

What is the biggest obstacle in Glaucoma management?

​

Eye pressure (IOP) can only be measured for a few seconds per patient per year giving a very limited understanding of the patient's condition and making Glaucoma a very difficult disease to diagnose and treat.

Our Solutions

Smartlens, Inc. is a platform company aiming to address the biggest challenges in Glaucoma management.


Smartlens' flagship product miLens
is the first device capable of monitoring IOP anywhere, at any time. It is similar to a daily contact lens and will significantly improve Glaucoma management as a
non-invasive, electronics free,
ultra sensitive, and easy to use device.


Smartlens' THERmic applies microdose personalized treatments based on the patient’s diurnal IOP. THERmic can work with all types of Glaucoma medications. 


Smartlens owns a broad portfolio of clinical stage technologies that will improve Glaucoma management. 

 

Eye Pressure (IOP) Matters

eyegraphics_edited.png
eyegraphics_edited.png
eyegraphics_edited.png
More than 5 million people are currently being treated for Glaucoma in the U.S., while an estimated 50% of Glaucoma sufferers are undiagnosed ​​
​Reducing eye pressure is the only known way of slowing down or stopping the progression of Glaucoma
 More than 140 million people are suffering from Glaucoma worldwide; and that number is expected to reach 300 million by 2040
bottom of page